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Smumuary Eighteen patients with inoperable hepatocellular carcinoma (HCC) were treated with intrahepatic
arterial yttrium-90 microspheres. All these patients showed a lung shunting below 15% and a tumour-to-
normal ratio higher than 2 as determined by diagnostic technetium-99m macroaggregated albumin (Tc-MAA)
gamma scintigraphy. The treatment was given through an arterial port placed during laparotomy. The
radiation doses to the liver and tumour were determined intraoperatively with a beta probe and liquid
scintillation counting of multiple liver biopsies. The treatment was well tolerated without major complications.
In all patients the tumour marker fell to a level which ranged from 41% to 0.2% of the pretreatment level.
Tumour regression was found to be dose related. Progressive or static disease occurred in a higher proportion
of patients whose tumours received <120 Gy (P = 0.005). Survival was better in those whose tumours received
> 120 Gy (median survival = 55.9 weeks) than those whose tumours received lower doses (median sur-
vival = 26.2 weeks). This difference is statistically significant with P = 0.005. We conclude that yttrium-90
microsphere therapy is safe and that tumour response is dose related. A tumour dose of > 120 Gy is
recommended.
Surgery remains the only hope of cure for patients with
hepatocellular carcinoma (HCC) (Maclintosh & Minuk,
1992). Unfortunately, most patients have inoperable tumours
at the time of presentation, and their prognosis is so dismal
that the median survival time is usually less than 2 months
(Okuda et al., 1985; Shiu et al., 1990), although longer
survivals have been reported in the literature (Yamada et al.,
1983; Kajanti et al., 1986; Epstein et al., 1991). Extensive
trials with systemic chemotherapy have yielded disappointing
results (Friedman. 1983). An increased response rate is
reported for hepatic arterial chemotherapy for these tumours,
but there is no good evidence that this technique prolongs
survival (Malik & Wrigley, 1988).
In an attempt to improve on the results of locoregional
therapy for inoperable HCC, intrahepatic arterial lipiodol
iodine-131 or yttrium-90 microspheres have been used with
varying degrees of success (Kobayashi et al., 1986; Park et
al., 1987; Bretagne et al., 1988; Houle et al., 1989; Novell et
al., 1991). A choice still exists between these two
radioisotopes for therapeutic purposes (Park et al., 1987;
Novell et al., 1991). Theoretically, yttrium-90 is more suitable
for therapy for larger tumours because of its higher energy,
thus providing a deeper penetration and a higher tumour
dose rate (Park et al., 1987; Lau & Li, 1992). Radiation
protection is also easier with a pure beta emitter (Lau & Li,
1992).
The safety and efficacy of yttrium-90 microspheres have
been attested in clinical studies involving reasonably large
numbers of patients with metastatic liver cancer (Blanchard
et al., 1989; Gray et al., 1992). The clinical experience in
HCC is more limited. A phase I study was conducted on ten
patients with HCC to determine the toxicities and tumour
response to increasing radiation doses (Houle et al., 1989).
Another phase I trial on ten patients with escalation of dose
had previously been reported by the same group (Shepherd et
al., 1992). In other series of patients with malignant liver
tumours, three additional patients with HCC were treated
with yttrium-90 microspheres (Blanchard et al., 1989; Herba
et al., 1988; Mantravadi et al., 1982). The experience of
yttrium-90 microsphere therapy in metastatic liver tumours
cannot be extrapolated to that of primary HCC. Primary
HCCs are usually larger, more vascular and frequently
supenmposed on cirrhotic livers with impaired liver function
and are associated with portal hypertension and extrahepatic
artenovenous shunting (Foster & Berman, 1977).
This phase I and II study aims to determine the optimum
dose of radiation that can be administered, and the response
and complication rates of hepatic arterial yttrium-90 micro-
spheres in inoperable HCC.
Patients and methods
Patients
From November 1990 to May 1993, 18 patients with
inoperable HCC were entered into the study. The diagnosis
of HCC was based on raised alphafetoprotein (AFP) of more
than 500 ng ml1' and ultrasound evidence of liver tumour or
histological proof. The inclusion criteria were: age <75
years, adequate liver function with bilirubin <50jimoll-1,
Karnofsky performance score of >70%, no serious associ-
ated medical illness that precluded a patient from lapar-
otomy, no extrahepatic spread of disease on preoperative
investigations, no major vessel involvement by tumour in-
cluding the main portal vein, main hepatic artery, hepatic
veins or inferior vena cava on preoperative investigations.
Other pre-entry investigations included full blood count,
liver and renal function tests, clotting profile, hepatitis B
surface antigen, serum AFP and ferritin levels, chest radio-
graphy and ultrasound scan of the liver. Suitable patients
were then subjected to selective hepatic angiography (HAG)
with technetium-99m-labelled macroaggregated albumin
(Tc-MAA) scan for assessment of percentage lung shunting
and tumour-to normal (T/N) ratio.
Selective HAG + Tc-MAA scan
The technique, which has been reported previously (Lau et
al., 1994; Leung et al., 1994), is briefly described below.
Selective HAG was performed with the usual Seldinger tech-
nique. The tip of the angiographic catheter was placed in the
hepatic artery distal to the origin of the gastroduodenal
artery. Through this catheter 20;Lg of angiotensin II (Ciba-
Geigy) was given over a period of lO s, followed by 111 MBq
(3 mCi) of Tc-MAA (Amersham Pulmonate II, 10-100 ,.m
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and average 30 im in size) 30 s later. Gamma scintigraphy of
the liver and lungs was then performed. The image of the
liver obtained was compared with an ultrasonogram, com-
puterised tomogram and tin colloid liver scan for tumour
localisation. The TfN ratio was determined by quantifying
the count per unit cell over various areas of the liver. The
count over both lungs divided by the total count over the
lungs and the liver gave the lung shunting percentage.
Patients are considered suitable for yttrium-90 microsphere
treatment if they satisfy the following criteria: lung shunting
of Tc-MAA less than 15%, no significant shunting of activity
to the gastrointestinal region, no multiple and complicated
arterial blood supply to the liver on HAG, T/N ratio of
Tc-MAA of more than 2.
Administration ofyttriwn-90 microspheres and determination
ofradiation doses
The treatment procedure and measurement of radiation doses
have been published (Lau et al., 1994), and a summary of the
methods is given below. Informed consent was obtained from
patients before treatment. Patients were subjected to lapar-
otomy and intraoperative ultrasound to document the site
and size of the liver tumours. Cholcystectomy and ligation
of the right gastric artery was then performed followed by
cannulation of the gastroduodenal artery with a Port-A-
Catheter (Pharmacia Deltec, St Paul, MN, USA). Perfusion
of both lobes of liver was checked by infusion of IOml of
3% fluorescein (Fluorescite, Alcon Laboratories) and inspec-
tion of the liver with a Wood's lamp. The catheter was then
connected to a four-way valve fixed on an injection bracket
made with 1 cm-thick Perspex. A 20Fig aliquot of angioten-
sin II was pulsed into the Port-A-Catheter over a period of
10 s. Thirty seconds later a predetermined fraction of
yttrium-90 microspheres (resin-based microspheres,
29-35pm in size, containing yttrium-90 at an activity of
approximately 30 Bq per microsphere, 3.3 x 107 spheres per
GBq, supplied by the Australian Nuclear Science and
Technology Organisation, Sydney, Australia) was pulsed.
Allowing 10 min for equilibrium, a solid-state beta probe
(Radiation Monitoring Devices), calibrated against a rubber
phantom containing standardised yttrium-90 silicate solution
(Amersham) of different known radioactivity concentrations,
was used to count the beta radiation emitting from the
surface of the tumorous and the non-tumorous parts of the
liver. Usually more than 20 readings were taken over each of
these areas. The mean count rate was converted to radioac-
tivity concentration (activity per unit volume) based on the
calibration curve obtained with the rubber phantom. The
mean radiation dose over the complete decay of yttrium-90
was then calculated using the formula from Berger (1971)
assuming a uniform distribution of the microspheres and
assuming that the microspheres remained in place without
biological clearance. Further injections of angiotensin II fol-
lowed by yttrium-90 microspheres were then made in order
to increase the radiation dose to the desired level. When the
desired radiation level was reached, incisional and Tru-cut
biopsies were then taken from the tumour and the non-
tumour parts of the liver. These were used for histopatho-
logical study and for verifiction ofthe radiation levels in the
tissue by the lquid stillationmhod. The biopsy specmens
for liquid scintillation counts were cut into small suitable
pieces of less than 0.1 g each and weighed. Each sample was
moistened with 5011 of distlld water folowed by digestion
using 1 ml of tissue solubilser (Protosol from DuPont). The
mixture was incubated at 59C for 16 h. Then 50i1 of EDTA
solution, I ml ofdistilled water, 50p1 ofglaial acetic acid and
10ml of liquid scintilant wee added. The solution was well
shaken and was counted in a liquid tillation counter (Beck-
man LS3801) with a yttrium-90/strontium-90 stamard (Amer-
sham). The concentration ofradioactivity in the tumorous and
non-tumorous parts of the liver and hence the radiation doses
were then computed. The operation ended with connection of
the catheter to a port which was buried subcutaneously in the
left lower chest wall.
After the operation, patients were nursed in an isolation
ward and were discharged home 10 days after surgery when
the radiation had decayed to a safe level and the wound had
adequately healed.
Monitoring and definition ofresponse
In patients in whom the AFP was raised, blood was taken
for measurement of the tumour marker on the day before
surgery, then daily for 7 days, then once every 3 days until
discharge from hospital. During follow-up blood was taken
once every 2-4 weeks. For patients who had low baseline
(<300 ng ml-') AFP, serum ferritin level was used for moni-
toring the response (Melia et al., 1983; Nakano et al., 1984).
At each of the follow-up visits, the Karnofsky score of the
patient was recorded.
Computerised tomography (CT) was used to measure
tumour volume and quantify regression of the tumour. This
was done routinely before and 2 months, 4 months, 6 months
and I year after the procedure. All CT scans were submitted
to an independent radiologist, who manually traced areas of
normal liver parenchyma and tumour involvement through
the full thickness of the liver for all scan slices. These were
then digitalised and the volumes of normal liver parenchyma
and tumour were calculated by a computer.
Interpretation of CT scans and follow-up of the size of the
tumour were assisted by ultrasonograms, which were taken at
2-monthly intervals, and by tin colloid liver scan at the end
of the third month after therapy. The end points to be
measured are degree of maximum tumour response, the dura-
tion of time to progression and ultimately survival calculated
from the time of diagnosis.
A complete response (CR) is defined as the disappearance
of all known lesions on radiological grounds and normalisa-
tion of AFP for at least 4 weeks. A partial response (PR) is a
decrease of 50% or more in the tumour volume and/or a
decrease of more than 50% in AFP or ferritin level for at
least 4 weeks. There should be no new appearance of lesions
or progression of lesions. Static disease (SD) is defined as a
decrease in tumour volume of less than 50% or an increase
in tumour volume of not more than 25%. Progressive disease
(PD) is an increase in tumour volume of more than 25% or
the appearance of new lesions. Any increase in AFP or
ferritin level after treatment is defined as static disease.
Monitoring oftoxicities
For monitoring of toxicities, renal and liver functions tests
were performed at the same time for each blood sample
taken for AFP measurement. Symptoms such as pain and
nausea were recorded daily and on each follow-up visit.
Repeat treatment with yttrium-90 microspheres was given in
patients with definite proof of disease progression.
Reslts
From November 1990 to May 1993, we treated 18 patients
with inoperable HCC using yttrium-90 microspheres. There
were 17 males and one female. Age ranged from 18 to 74
years with a median of 52 years. Details of these 18 patients
are shown in Table I.
Two patients were found to have extrahepatic spread of
the disease on intraoperative ultrasound. One had a tumour
thrombus in the right hepatic vein and another had a small
peritoneal secondary. We decided to proceed with yttrium-90
microsphere treatment. Both patients died of progressive
disease, one 2 months and one 4 months after treatment. The
rest of the patients underwent the full treatment and were
available for disease and toxicity evaluations.
Response ofserun tunour markers to yttriun-90 microspheres
Ten of the 18 patients had raised AFP (>300ngmlV')
before treatment. A drop of 80% or more in AFP level after96 W.-Y. LAU et al.
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treatment occurred in eight of these ten patients, and the
level decreased by more than 50% in the other two patients
(Figure 1). The greatest drop of 99.8% in AFP occurred in a
49-year-old man with a 12 cm tumour.
In the eight patients with low preoperative AFP, serum
ferritin was assayed. The ferritin level showed a transient rise
and then decreased gradually to less than 50% of the peak
value in all these patients (Figure 2).
Response oftumour volumes to yttriwn-90 microspheres
On the follow-up CT scans for the 16 patients without
extrahepatic disease, no patient had a complete response.
Partial response occurred in seven of eight patients who
received > 120 Gy to all the tumours compared with one of
eight patients who received <120 Gy to at least one of the
tumour nodules. The difference is statistically significant
(Fisher's test, P = 0.005).
Determination ofoptimal tumour dose
The radiation doses measured by the beta probe correlated
well with those determined from liquid scintillation
(coefficient of linear regression r = 0.96). For simplicity only
the doses from intraoperation beta probe measurement are
listed (Table I). The response of tumours to radiation was
dose related. An optimal tumour dose should be > 120 Gy.
The dose delivered to the tumour was determined by the T/N
ratio and the maximum dose we delivered to the normal part
of the liver. Initially we started with <30 Gy to the non-
tumour part of the liver. We gradually stepped up the radia-
tion dose to the non-tumour part of the liver so that tumours
received higher doses of irradiation. We found out that the
non-tumour part ofthe liver with a cirrhotic background was
able to tolerate about 70 Gy of radiation without evidence of
radiation hepatitis.
Complications ofselective internal radiation therapy
No operative mortality and major complication arose from
yttrium-90 microsphere treatment. The treatment was well
tolerated in most patients without nausea or vomiting, symp-
toms which are commonly associated with chemotherapy. No
bone marrow suppression was documented.
Patient survival after yttrium-90 microspheres
The median survival of all patients who received yttrium-90
microspheres was 30.6 weeks. Excluding the two patients
with extrahepatic disease who died 2 and 4 months after
treatment, the median survival became 35 weeks (Figure 3).
Those in whom all tumours received radiation doses greater
than 120 Gy did better than those in whom at least one
tumour nodule received less than 120 Gy. The median sur-
vival for these two groups was 55.9 weeks and 26.2 weeks
respectively (Figure 4), and the difference is statistically
significant, with P = 0.005.
Disusssiom
External megavoltage radiotherapy has been regarded as
ineffective for hepatocellular carcinoma (Geddes & Falkson,
1970). Heptocellular carcinomas will respond to radiotherapy
if the radiation dose delivered to the tumours is sufficiently
large. The limiting factor is the low tokrance of hepatocytes
to whole-liver irradiation without causing radiation hepatitis
(Ingold et al., 1965; Concannon et al., 1967), thus preventing
the ability to deliver tumoricidal doses, which should exceed
120Gy to induce tumour response (Yoo et al., 1989).
The concept of embolising yttrium-90 microspheres into
the liver through its arterial blood supply to treat liver cancer
is not new. Liver tumours are supplied almost exclusively by
the hepatic artery, as opposed to the portal vein (Breedis &
Young, 1954). Radioactive microspheres, when injected into
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the hepatic artery of patients with liver tumour, concentrate
preferentially in the tumour rather than in non-tumour part
of the liver. Vasoactive agents such as angiotensin II have
been demonstrated to enhance the flow of these microspheres
into the tumour and away from the non-tumour liver by
their vasoconstrictive action on the normal blood vessels but
not on the abnormal neovasculature (Gray et al., 1992). As a99 W.-Y. LAU et al.
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result, hepatic arterial injection of radioactive microspheres
offers the potential for delivery of high radiation doses to the
tumour, with low radiation doses to the non-tumour part of
the liver and very low systemic radiation exposure to the rest
of the body. This therapeutic concept of hepatic arterial
microsphere injection was first reported by Prinzmetal et al.
in 1948. Subsequent clinical application of this concept
yielded encouraging results (Grady, 1979; Ariel & Padula,
1982; Mantravadi, 1982). However, these results were
achieved with two major side-effects of yttrium-90 treatment,
namely leaching of yttrium-90 from the resin or ceramic
matrix with accumulation of the isotope in bone, leading to
bone marrow suppression, and the embolic effects of the
infusing microspheres, resulting in shunting of the spheres to
the lungs and other organs and leading to pulmonary fibrosis
and gastrointestinal bleeding (Novell et al., 1991). In fact, 3
of 25 of patients in one series died from complication of the
treatment (Grady, 1979).
Improvements in radiolabelling technique have resulted in
much more stable yttrium-90 microspheres (Lau & Li, 1992).
Newer glass microspheres (Theraspheres, Theragenics,
Atlanta, GA, USA) and newer resin microspheres (supplied
by the Australian Nuclear Science and Technology Organis-
ation) have overcome the problem of leaching. A rouine test
on the resin yttrium-90 microspheres before treatment of our
patients showed that less than 0.1% of the activity leaches
from the microspheres. Clinical studies on metastatic liver
cancer using these newer glass (Herba, 1988; Blanchard et al.,
1989; Houle et al., 1989) and resin microspheres (Gray et al.,
1992) have produced good results with very little toxicity.
Our low complication rate of internal radiation therapy
attests to the safety of the newer resin yttrium-90 micro-
spheres.
The pretreatment Tc-MAA scan allowed us to exclude
patients with low T/N ratio (<2) and those at risk of
developing radiation-induced pulmonary fibrosis or gastro-
intestinal complications owing to arteriovenous shunting of
radioactivity from the liver to these organs.
Yttrium-90 microspheres can be given through an angio-
graphic catheter in the hepatic artery placed through a
femoral puncture usng the Seldinger technique (Houle et al.,
1989). The main disadvantage of this technique is the
inability to measure directly the radiation dosage to the
tumour and non-tumour part of the liver because yttrium-90
is a pure beta emitter and its maximum range in soft tissue is
only 1.1 cm. Also, yttrium-90 microspheres entering into the
cystic artery can cause radiation cholcystitis, and into the
gastroduodenal and nght gastnc artenes can cause gastro-
intestinal bleeding.
Gray et al. (1992) have developed and refined a technique
for the treatment of metastatic liver cancer using yttrium-90
microspheres and called it selective internal radiation therapy
(SIR therapy). This technique consists in cholcystectomy,
ligation of the right gastric artery, cannulation of the gastro-
duodenal artery and injection of yttrium-90 microspheres
Median survival = 55.9 weeks
P=0.005
Median survival = 26.2 weeks
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following angiotensin II therapy. We used this technique for
the treatment of primary HCC, but it was necessary to
reduce the dose of angiotensin II to 20jg because of the
possible problem of worsening the portal hypertension. The
use of an intraoperative beta probe allowed dit assessment
of the radiation dosage to the tumour and non-tumour parts
of the liver and other intra-abdominal organs.
Experience with yttrium-90 microspheres in the treatment
of HCC suimposed on cirrhosis is very limited. Phase I
studies were conducted in 20 patients by injecting glass
yttrium-90 microspheres through an angiographic catheter
(Houle et at., 1989; Shepherd et al., 1992). The actual radia-
tion dosage was not directly measured in these studies. The
administered amount of yttrium-90 microspheres was based
on the volume of the patient's liver and the desire total
radiation dose to the viver assuming a uniform distribution of
the microspheres within the hepatic parenchyma. The radia-
tion dose ived by the tumour was esumated with a
partitioning model for dose calculation by assuming that the
intrahepatic distnbution of the yttrium-90 microspheres was
identical to that of the technetium-99m-labelled macroaggre-
gated albumin. This assumption may not be strictly true
because of the higher density and much greater number of
the glass microspheres. The results showed that for the
estimated absorbed doses of between 50 and 100 Gy to the
non-tumour part of the liver, no toxicities were observed and
all patients who had stable disease were treated with higher
doses of radiation. The small numbers of patients treated,
however, do not permit firm conclusions to be drawn concer-
ning the relationship between dose and response. Our direct
measurement of the radiation dose during surgery enabled us
to monitor accurately the radiation dose to the non-tumour
part of the liver and to escalate the radiation dose to the
tumour with safety. Our results showed that the cirrhotic
non-tumour part of the liver can tolerate radiation up to
70Gy without development of radiation hepatitis. Fox et al.
(1991) advocated that the radiation dose to the normal liver
during treatment of metastatic liver tumours should be ap-
proximately 80 Gy, which is higher than our recommenda-
tion regarding cirrhotic livers with impaired function. From
the detailed analysis of a cubic centimetre of normal liver
tssue after SIR therapy, they discovered a highly hetero-
geneous dose pattern resulting from the microspheres behav-
ing as series of discrete point sources and they found that
one-third of the normal liver tissue received less than 33.7%
of the doses predited by assuming a homogeneous distribu-
tion of 90 Gy.
Thus, the recommended doses of 70 Gy in cirrhotic liver
and 80 Gy in normal liver are average doses with many
non-tumour liver parenchymal cells receiving much less than
this dose and therefore being spared. This is completely
different from whole-liver irradiation using external beams in
which all liver cells within the treatment field receive the
same radiation dose and the upper limit of 30-40Gy for
external radiation should not be exceeded.
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Our phase I and II study showed that HCC responds to
hepatic arterial yttriunm-90 microspheres well with very little
toxicity. With adequate radiation doses delivered to the
tumours, there was a decrease in tumour markers, a decrease
in tumour size and prolongation of patient survival. Our
results suggest that a case-control phase II study should
now be conducted.
Refernces
ARIEL. IM. & PADULA. C. (1982). Treatment of asymptomatic
metastatic cancer to the liver from primary colon and rectal
cancer by intraarterial administration of chemotherapy and
radioactive isotopes. J. Surg. Oncol., 209, 151-156.
BERGER. MJ. (1971). Distribution of absorbed dose around point
sources of electrons and beta particles in water and other media.
J. Nucl. Med. NM/MIRD Suppl. 5. Pamphlet No. 7, 7-23.
BLANCHARD. KJ.. MORROW. IM. & SUTHERLAND. JB. (1989).
Treatment of liver tumors with yttrium-90 microspheres alone.
Can. Assoc. Radiol. J.. 40, 206-210.
BREEDIS. C. & YOUNG. G. (1954). The blood supply of neoplasms in
the liver. Am. J. Pathol.. 30, 969-985.
BRETAGNE. J.. RAOUL. J.. BOURGUET. P.. DURAUFERRIER. R..
DENGNIER. Y.. FAROUX. R.. RAMEE, A.. HERRY, JY. & GAS-
TARD. J. (1988). Hepatic artery injection of 1-131-labelled
Lipiodol. II. Preliminary results of therapeutic use in patients
with hepatocellular carcinoma and liver metastases. Radiology,
168, 547-550.
CONCANNON. JP.. EDELMANN. A.. FRICK J.C. & KUNKEL, G.
(1967). Localised 'radiation hepatitis' as demonstrated by scintil-
lation scanning. Radiology. 89, 136-139.
EPSTEIN. B.. ETLINGER. D. LEICHNER. P. & ORDER. S.E. (1991).
Multimodality cisplatin treatment in nonresectable alpha-
fetoprotein positive hepatoma. Cancer. 67, 896-900.
FOSTER. J.H. & BERMAN. M.M. (1977). Primary epithelial cancer in
adults. In Solid Liver Tumors. Foster, J.H. & Berman, M.M.
(eds) pp.62-104. W.B. Saunders: Philadelphia.
FOX. R.A.. KLEMP. P.F.B.. EGAN. G.. MINA. L.L.. BURTON. M A &
GRAY. G.A. (1991). The dose distribution following selective
internal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 21,
463-467.
FRIEDMAN. M.A. (1983). Primary hepatocellular cancer: present
results and future prospects. Int. J. Radiat. Oncol. Biol. Phs., 9,
1841-1850.
GEDDES. E.W. & FALKSON. G. (1970). Malignant hepatoma in the
Bantu. Cancer. 25, 1271-1278.
GRADY. E.D. (1979). Internal radiation therapy of hepatic cancer.
Dis. Colon Rectum, 22, 371-375.
GRAY. B-N.. ANDERSON. J.E.. BURTON. M.A.. HAZEL G.V.. COD-
DIE. J.. MORGAN. C. & KLEMP. P. (1992). Regression of liver
metastases following treatment with yttnrum-90 microspheres.
Aust. NZ J. Surg., 62, 105-110.
HERBA. MJ.. ILLESCAS. F.F.. THIRLWELL. M.P.. BOOS. GJ.. ROSEN-
THALL. L.. ATRI. M. & BRET. P.M. (1988). Hepatic malignancies:
improved treatment with intraarterial yttrium-90. Radiology, 169,
311-314.
HOULE, S., YIP, T., SHEPHERD, F., ROTSrEIN, L.E., SNIDERMAN,
K.W., THEIS, E., CRAWTHORN, RH. & RICHMOND-COX, K.
(1989). Hepatocellular carcinoma: pilot trial of treatment with
Yttrium-90 microsphres. Radiology, 172, 857-860.
INGOLD, JA. REED, G.B., KAPLAN, H.S. & BAGSHAW, MA. (1965).
Radiation hepatitis. Am. J. Roenigenol. Radiun Ther. Nucl. Med,
93, 200-208.
KAJANTI, M., RISSANEN, P., VIRKKUNEN, P., FRANSSIIA, K. &
MANTYLA., M. (1986). Regional intra-arterial infusion ofcisplatin
in primary hepatocellular carcinoma. A phase H study. Cancer,
58, 2386-2388.
KOBAYASHI, H., HIDAKA, H., KAJAYA, TANOUE, H., INOUE, K.,
IKEDA, M., NAKAJO, M. & SHINOHARA, S. (1986). Treatment of
hepatocellular carcinoma by transarteral inection of antcancer
agents in iodized oil suspension or of radioactive iodized oil
solution. Acta Radiol. Diagn., 27, 139-147.
LAU. WY. & LI, AK.C. (1992). Therapeutic aspects of radioisotopes
in hepatobiliary malignancy. Br. J. Surg., 79, 711.
LAU. W.Y.. LEUNG. T.W.T.. HO. S.. CHAN. M.. LEUNG. N.W.Y.. LIN.
J., METREWELI. C. & LI. AK_C_ (1994). Diagnostic pharmaco-
scintigraphy with technetium-99m macroaggregated albumin in
the prediction of tumour to normal uptake ratio during therapy
of inoperable hepatocellular carcinoma with yttrium-90 micro-
spheres. Br. J. Radiol., 67, 136-139.
LEUNG. WT.. LAU. WY.. HO. S.K.W.. CHAN. M.. NANCY. WY.,
LEUNG, N.W.Y.. LIN. J_ METREWELI. C.. JOHNSON, PJ. & LI.
A.K.C. (1994). Measuring lung shunting in hepatocellular car-
cinoma with intrahepatic-arterial technetium-99m macroaggre-
gated albumin. J. Nucl. Med., 35, 70-73.
MACLINTOSH. EL. & MINUK. GY. (1992). Hepatic resection in
patients with cirrhosis and hepatocellular carcinoma. Surg.
Gvnecol. Obstet.. 174, 245-254.
MALIK. S.TA. & WRIGLEY, P.F.M. (1988). Intra-arterial hepatic
chemotherapy for liver malignancy. Br. Med. J., 297, 434.
MANTRAVADI. R.V.P., SPIGOS. D.G., TAN, W.S. & FELIX, E.L. (1982).
Intraarterial yttrium-90 in the treatment of hepatic malignancy.
Radiology, 142, 783-786.
MELIA. W.M., BULLOCK, S., JOHNSON, PJ. & WILLIAMS. R (1983).
Serum ferritin in hepatocellular carcinoma. Cancer, 51,
2112-2115.
NAKANO, S.. KUMADA, T., SUGIYAMA. K.. WATAHIKI, H. &
TAKEDA. I. (1984). Clinical significance of serum ferritin deter-
mination for hepatocellular carcinoma. Am. J. Gastroenterol.,
623-627.
NOVELL, JIR.. HILSON. A. & HOBBS. K.E.F. (1991). Therapeutic
effects of radio isotopes in hepatobiliary malignancy. Br. J. Surg.,
78 901-906.
OKUDA. K.. OHTSUKI. T.. OBATA, H., TOMIMATSU, M., OKAZAKI
N.. HASEGAWA, H. & NAKAJIMA, Y. (1985). Natural history of
hepatocellular carcinoma and prognosis in relation to treatment.
Cancer, 56, 918-928.
PARK. C.H.. SUH. J.H., YOO, H.S., LEE, J.T., KIM, DI. & KIM. B.S.
(1987). Treatment of hepatocellular carcinoma (HCC) with
radiolabelEd lipiodol: a preiminary report. NucL. Med. Commun.,
8, 1075-1087.
PRINZMETAL M.. ORNITZ, Jr, E.M., SIMKIN, B. & BERGMAN, H.C.
(1948). Arteriovenous anastomoses in liver, spleen and lungs. Am.
J. Physiol., 152, 48-52.
SHEPHERD. FA.. ROTSEIN. L.E., HOULE, S., YIP, T.C.K., PAUL K. &
SNIDERMAN, K.W. (1992). A phase I dose escalation trial of
yttrium-90 microspheres in the treatment of primary hepatocel-
lular carcinoma. Cancer, 70, 2250-2254.
SHIU. W.. DEWAR. G.. LEUNG. N., LEUNG. W.T., CHAN. M.. TAO,
M.. LUL C.. CHAN, C.L. LAU. W.Y.. METREWELI. C. & LI, A-K.C.
(1990). Hepatocellular carcinoma in Hong Kong clinical study
on 340 cases. Oncology, 47, 241-245.
YAMADA, R, SATO KAWABATA, NAKATSUKA, H.. NAKAMURA,
K. & TAKASHIMA, (1983). Hepatic artery embolization in 120
patients with unresectable bepatoma. Radiology, 148, 397-401.
YOO, H.S.. PARK, C.H.. SUH, J.H., LEE, J.T., KIM, D.I., KIM, B.S. &
MADSEN. M.T. (1989). Radioiodinated fatty acid esters in the
management of hepatocellular carcinoma: preliminary findings.
Cancer Chemother. Pharmacol., 23 (Suppl.), S54-S58.